SNCA and multiple system atrophy: Although rare, FTLD‐synuclein cases expand the clinicopathological spectrum of both MSA and FTLD and have implications for our understanding of selective neuronal vulnerability in MSA and the interpretation of biomarker studies, such as those using α‐synuclein seed amplification assays and α‐synuclein positron emission tomography.